Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New intimate cream passes skin safety test in small study

NCT ID NCT07533474

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a cream called GINPI on 20 healthy women to see if it is safe and feels good on the skin in the intimate area. The women used the cream normally and then answered questions about how it felt, looked, and smelled. The main goal was to confirm the cream does not cause irritation and is pleasant to use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Jun 2024

Finished

Jul 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy women * Age between 18 and 65 years * Volunteers with sensitive skin (50%) and normal skin (50%) * Volunteers with Fitzpatrick skin photo-type I to IV * Adequate cultural level and understanding of the clinical study * To agree to participate voluntarily in the study and grant written Informed Consent. Exclusion Criteria: * Volunteers with chronic or acute disease at study initiation or in the last 3 weeks prior to inclusion * Volunteers with skin pathologies in the last 3 weeks prior to study initiation. * Volunteers under pharmacological treatment. * Pregnant or breast-feeding women. * Volunteers with allergy to any of the study product components. * Vaccinated in the last 3 weeks previous to study start.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Skin aging, dry skin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Anmar Clinical Services, S.L.U.

    Pamplona, Navarre, 31003, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.